R&D channel feed – Endpoints News

R&D channel feed

After calling a lengthy time out on the development field, Allogene finally kicks off a landmark PhII pivotal

3 years ago

R&D acceleration: Amgen opens its second largest research site, with lab and office space for 650 staff

3 years ago

With FDA decision one month away, Provention partners with Sanofi on US marketing for type 1 diabetes drug

3 years ago

In add-on to eye disease pipeline, Boehringer pays Surrozen to acquire rights to Wnt drug

3 years ago

AstraZeneca taps two more targets from its AI partner, again in CKD and IPF

3 years ago

Ironwood's former pipeline spinout hits another speed bump, laying off 45% and turning toward the mitochondria

3 years ago

Aldeyra touts first part of PhIII for rare eye disease but questions remain as FDA meeting approaches

3 years ago

UC Davis microbiome spinout rebrands infant supplement business with nature focus

3 years ago

Eliem says earlier drug exposure issues have been resolved, drops one epilepsy indication

3 years ago

GSK touts topline win for PD-1 in head-to-head with Keytruda — while steering next big checkpoint drug into PhIII

3 years ago

Penny stock, Merck partner lays off 45% of staff to reach PhII readout by early 2023

3 years ago

Astellas, Pantherna add organ to mRNA tie-up; Rocket launches sale of six figures worth of stock

3 years ago

KalVista ends a PhII study early after patients suffer severe and life-threatening side effects

3 years ago

Penny stock player to review all options to try staying afloat after clinical trial fail

3 years ago

Tiny Vergent seals modest Series B in pursuit of cancer imaging agent

3 years ago

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

3 years ago

Mesoblast sends in improved potency assay, looking to resubmit to FDA on acute graft-versus-host disease drug

3 years ago

Startup's gold nanocrystal ALS drug flops a PhII trial, a reminder of the disease's obstacles despite Amylyx OK

3 years ago

Scandion's shares fall after oncology biotech reports PhII fail

3 years ago

Myovant board balks as majority owner Sumitomo swoops in with a $2.5B deal to buy them out

3 years ago

FDA greenlights Otsuka subsidiary's bile duct cancer drug

3 years ago

#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug

3 years ago

#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapy

3 years ago

#AAO22: Iveric Bio, undeterred by looming PDUFA for competitor, touts subgroup data on GA drug

3 years ago

First page Previous page 116 117 118119120 121 122 Next page Last page